Stockscreener 앱 받기
4.24
7.61%
0.30
전일 마감가:
$3.94
열려 있는:
$4.24
하루 거래량:
676.92K
Relative Volume:
1.14
시가총액:
$130.39M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-3.1588
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+8.72%
1개월 성능:
+16.16%
6개월 성능:
+78.53%
1년 성능:
+36.33%
1일 변동 폭
$4.20
$4.6499
1주일 범위
$3.69
$4.6499
52주 변동 폭
$1.90
$4.6499
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
4.25 | 120.88M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.77 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.78 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.57 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
810.20 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
179.10 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Vistagen (NASDAQ: VTGN) completes PALISADE-3 Phase 3; topline results due year end - Stock Titan
Is Vistagen Therapeutics Inc. a candidate for recovery playPortfolio Risk Summary & Risk Controlled Daily Trade Plans - newser.com
Vistagen Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Can Vistagen Therapeutics Inc. stock deliver surprise earnings beatPortfolio Risk Summary & Fast Gaining Stock Strategy Reports - newser.com
What dividend safety score for Vistagen Therapeutics Inc. stockQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Strategies to average down on Vistagen Therapeutics Inc.Risk Management & Safe Entry Zone Identification - newser.com
Will breakout in Vistagen Therapeutics Inc. lead to full recoveryEarnings Miss & High Return Trade Opportunity Guides - newser.com
Will Vistagen Therapeutics Inc. stock benefit from green energy trends2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is Vistagen Therapeutics Inc. stock a safe haven assetWeekly Stock Recap & High Accuracy Trade Alerts - newser.com
Should you hold or exit Vistagen Therapeutics Inc. nowWeekly Risk Summary & Weekly Watchlist for Hot Stocks - newser.com
Vistagen Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Reactions & Intraday High Probability Setup Alerts - newser.com
Technical signs of recovery in Vistagen Therapeutics Inc.CPI Data & Community Consensus Stock Picks - newser.com
Will Vistagen Therapeutics Inc. stock gain from strong economy2025 Volatility Report & Fast Entry and Exit Trade Plans - newser.com
Is Vistagen Therapeutics Inc. stock reversal real or fakeRecession Risk & Community Consensus Trade Signals - newser.com
Published on: 2025-11-01 04:45:37 - newser.com
Combining machine learning predictions for Vistagen Therapeutics Inc.CEO Change & Reliable Price Action Trade Plans - newser.com
How to recover losses in Vistagen Therapeutics Inc. stockJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Will Vistagen Therapeutics Inc. stock remain a Wall Street favoriteForecast Cut & Precise Buy Zone Identification - newser.com
How to escape a deep drawdown in Vistagen Therapeutics Inc.Day Trade & Low Risk Investment Opportunities - newser.com
VistaGen Therapeutics Appoints Paul R. Edick to Board - The Globe and Mail
Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer? - MSN
Published on: 2025-10-30 03:05:01 - newser.com
VistaGen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday - MarketBeat
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
0.21%
자본화:
|
볼륨(24시간):